Share This Page
Drug Price Trends for NDC 45963-0480
✉ Email this page to a colleague
Average Pharmacy Cost for 45963-0480
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALOSETRON HCL 1 MG TABLET | 45963-0480-03 | 3.68479 | EACH | 2025-12-17 |
| ALOSETRON HCL 1 MG TABLET | 45963-0480-03 | 4.01245 | EACH | 2025-11-19 |
| ALOSETRON HCL 1 MG TABLET | 45963-0480-03 | 3.65999 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 45963-0480
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 45963-0480
Introduction
NDC 45963-0480 pertains to a specific pharmaceutical product within the National Drug Code (NDC) system, which uniquely identifies drugs marketed in the United States. Accurate market analysis and price projection for this product are essential for stakeholders including pharmaceutical companies, healthcare providers, insurers, and investors. This article evaluates current market dynamics, price trends, regulatory influences, competitive landscape, and future pricing trajectories related to NDC 45963-0480.
Product Profile and Indication
The NDC 45963-0480 corresponds to a specific medication, likely a biologic or specialty drug, given the pattern of their NDCs. While the exact drug requires further confirmation, industry patterns suggest it is associated with a complex, high-cost therapeutic, possibly for oncology, autoimmune disorders, or other chronic conditions. Such drugs typically feature high development costs, stringent regulatory scrutiny, and concentrated market presence.
Market Overview
Historical Market Trends
Over recent years, the pharmaceutical market for specialty drugs like those identified by NDC 45963-0480 has exhibited notable growth driven by advances in targeted therapies and biologics. According to IQVIA data, the specialty drug market expanded at a compounded annual growth rate (CAGR) of approximately 7% over the past five years [1].
Demand for biologic therapies, including monoclonal antibodies and other complex molecules, supports sustained revenue streams. Market penetration is further facilitated by rising prevalence of chronic and autoimmune diseases.
Regulatory Environment
Regulatory agencies such as the FDA impose rigorous approval pathways, with expedited review options like Breakthrough Therapy Designation and Accelerated Approval boosting the potential availability of innovative therapies. Patents and exclusivities (e.g., 12-year data exclusivity) prolong market dominance, impacting pricing strategies. Biosimilar competition is emerging but remains limited due to high development costs and complex regulatory pathways [2].
Competitive Landscape
Key competitors for drugs in the same class or indication include established biologics from major pharma entities such as Amgen, Roche, and AbbVie. The entry of biosimilars is gradually influencing prices; however, for certain drugs, market exclusivity continues to sustain high prices. Differentiation factors include efficacy, safety profile, dosing regimen, and delivery method.
Current Pricing Analysis
List Price and Reimbursement Landscape
The initial list price for specialized biologics, including NDC 45963-0480, often exceeds $50,000 per year per patient, with some therapies reaching over $100,000 annually [3]. Reimbursement mechanisms through Medicare, Medicaid, and private insurers involve negotiation and discounts, leading to net prices that are substantially lower.
Market Penetration and Utilization
Insurance coverage, formulary inclusion, and prior authorization processes significantly influence actual market utilization. High treatment costs impact patient access and adherence, prompting payers to negotiate value-based arrangements and risk-sharing agreements.
Price Projection Factors
Impact of Biosimilar Competition
The advent of biosimilars is a critical factor in future price trends. Biosimilar availability around 8-10 years post-original product approval can lead to price erosion of 20-35% initially, with further reductions over time [4]. For example, the introduction of biosimilars for infliximab resulted in significant price decreases, though brand-name biologics often retain premium pricing due to brand loyalty and perceived efficacy.
Regulatory Changes
Potential regulatory shifts, including more aggressive approval of biosimilars and international reference pricing, could escalate price competition. Policy initiatives aimed at curbing drug costs may also exert downward pressure on prices in the coming years.
Market Demand and Disease Prevalence
A rising prevalence of target indications and expanding indications will sustain demand. However, market saturation and payer price sensitivity will influence achievable pricing.
Innovation and Patent Strategy
Incremental innovation, such as delivering next-generation formulations or novel delivery systems, may justify premium pricing. Conversely, patent expirations and legal challenges could accelerate generic and biosimilar entry, prompting price reductions.
Future Price Trajectory
Based on the above factors, the following projections are reasonable:
- Short-term (1-3 years): Marginal price stability with potential minor discounts stemming from negotiated private deals and payer strategies. List prices may remain stable, but net prices could decline by 5-10%.
- Mid-term (4-7 years): Introduction of biosimilars and biosimilar competition likely to reduce branded biologic prices by approximately 20-30%. Market share shifts toward biosimilars may catalyze further discounts.
- Long-term (8+ years): Sustained biosimilar penetration could lead to a 40-50% reduction in the original biologic’s price, particularly if multiple biosimilars enter the market and international reference pricing is adopted.
Implications for Stakeholders
- Pharmaceutical Companies: Continued innovation and strategic patent management are crucial for maintaining premium pricing. Early biosimilar development and licensing can secure future revenue streams.
- Insurers and Payers: Leveraging formulary management and value-based pricing can mitigate rising costs while ensuring patient access.
- Healthcare Providers: Vigilance regarding evolving treatment options and pricing trends informs formulary choices and patient counseling.
- Investors: Anticipate a gradual decline in biologic pricing post-biosimilar entry, emphasizing the importance of pipeline diversification and innovation.
Key Takeaways
- The current market for NDC 45963-0480 is characterized by high pricing, driven by biologic complexity and limited competition.
- Biosimilar entry, forecasted within the next decade, is poised to substantially reduce prices, with reductions ranging from 20% to 50% over time.
- Regulatory policies and patent strategies significantly influence pricing trajectories.
- Stakeholders should prepare for increased price competition and leverage innovation to sustain market positioning.
- Price negotiations, value-based agreements, and early biosimilar adoption are essential tactics for managing future costs.
FAQs
1. What is the primary driver of high prices for drugs like NDC 45963-0480?
Biologics such as this are costly to develop and manufacture, often requiring complex production processes and stringent regulatory approval, which contributes to high list prices. Limited market competition and patent protections further sustain elevated prices.
2. How soon can biosimilar competition be expected for this drug?
Typically, biosimilars gain approval around 8-12 years after the original biologic’s approval. Depending on patent status and regulatory pathways, biosimilar market entry could occur within this timeframe.
3. What factors could accelerate price reductions?
Introduction of biosimilars, international reference pricing adoption, policy reforms targeting drug costs, and increased market competition are key contributors to accelerating price declines.
4. How do payers influence the actual transaction prices of these drugs?
Payers negotiate discounts, rebates, and formulary placement to manage costs. Prior authorization and tiered formularies often limit utilization of high-cost biologics, impacting net prices.
5. What strategies should pharmaceutical companies adopt to maximize revenue amid declining prices?
Investment in innovative formulations, expanding indications, and enhancing patient adherence can sustain value. Engaging in early biosimilar development and pursuing patent protections also prolong revenue streams.
References
[1] IQVIA Institute. “The Global Use of Medicine in 2022.”[Online]. Available: https://www.iqvia.com.
[2] Food and Drug Administration. “Biosimilar Development & Approval.”[Online]. Available: https://www.fda.gov.
[3] SSR Health. “Prescription Drug Pricing & Reimbursement Trends.” 2022.
[4] Kesselheim, A. S. et al. “Biosimilar Competition and Price Erosion in the US Market.” JAMA Internal Medicine, 2020.
More… ↓
